This site is intended for healthcare professionals
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers

Publication digest

Read time: 15 mins
Last updated:17th Jan 2022
Published:17th Jan 2022

Take a deep dive into our publication digests to learn more about RET inhibitors and their impact on the treatment and management of non-small cell lung cancer (NSCLC) and thyroid cancers.

  • Explore the clinical evidence for RET inhibitors
  • Discover how testing for RET alterations impacts treatment
  • Find out more about molecular screening strategies to detect RET alterations

Identification of NTRK and RET fusion-positive thyroid cancers

Find out more on integrated molecular stratification strategies that can help identify patients who may benefit from RET or NTRK inhibitor treatment.

Learn more

RET, driver genes, and brain metastases in NSCLC

Next-generation sequencing analysis of a number of potential driver gene mutations uncovered potential risk factors for brain metastases in NSCLC.

Learn more

Imaging in NSCLC with RET rearrangements

Discover how RET+ NSCLC may show patterns of metastases and imaging features that are distinct from other mutations like ALK and ROS1.

Learn more

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer

Explore our publication digest for the evidence of antitumour activity demonstrated by selpercatinib in patients with RET fusion-positive NSCLC, including intracranial response to this targeted treatment.

Learn more